{
  "docId": "019de075-4071-7657-953a-43c246cbe714",
  "docSlug": "684835678957e07d55af9fc01c6da54e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 44,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "Slide 22 of a presentation deck; includes detailed footnotes defining medical acronyms and study parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4071-7657-953a-43c246cbe714/22",
  "deckHref": "/decks/019de075-4071-7657-953a-43c246cbe714",
  "deckJsonHref": "/decks/019de075-4071-7657-953a-43c246cbe714.json",
  "deckAnchorHref": "/decks/019de075-4071-7657-953a-43c246cbe714#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Clear rationale for targeting IL-33 in severe viral lung infection",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "135b3b08-c565-42ee-825d-e36b43ee0f56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.35,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Exacerbation risk increased by 5% every month Breztri treatment was delayed",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90493c75-4832-447d-8cf4-241675ccba78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.67,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Highlights importance of early diagnosis and concomitant K+ use in RAASi therapy",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa1a237c-0e54-446a-9a2e-3b15fc767c83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.36,
        "y": 0.5
      },
      "kind": "chart",
      "text": "Breztri exacerbation risk chart",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "970b8acb-a03a-4eb9-9002-28764a9a8865",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "1. Prompt initiation = initiated therapy ≤30 days, Delayed initiation = initiated therapy >30 - ≤180 days, Very delayed initiation = initiated therapy 180 days. 2. REVEAL-CKD multinational study... 3. Guidelines include: KDIGO...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83b293b9-1dbf-4e28-8640-806296c603f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.67,
        "y": 0.35
      },
      "kind": "list",
      "text": "REVEAL-CKD: 85-97% Stage 3 CKD undiagnosed; Delaying diagnosis of CKD by one year: 40% risk of deterioration, 63% risk of kidney transplant/long-term dialysis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e26de70-f697-4aeb-83a6-b092561fd2a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.67,
        "y": 0.58
      },
      "kind": "list",
      "text": "ZORA highlighted role of Lokelma for patients with HK whilst on RAASi; CKD and HF guidelines recommend and support use of K+ binders",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ecaceb7-7b11-48aa-ad0b-1931269196d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.36,
        "y": 0.35
      },
      "kind": "list",
      "text": "EROS: relationship between timing of Breztri initiation and exacerbation rate; Initiating <30 days resulted in 24% reduction in the risk of future exacerbations vs delaying treatment up to six months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7e44e10-9f68-4a17-965b-25faa6723e23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "list",
      "text": "Staining showed localised IL-33 in airway; IL-33red/sST2 levels associated with poor clinical outcomes; ST2 expressed in alveolar capillary cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0d52a49-f95b-44ca-bf73-682490d55b8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "ATS and ERA data highlights improvement in patient outcomes across R&I and CVRM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0370d998-5f91-4bba-b19b-dac88669443a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e42f8e1-1947-405f-a4c1-7b2dc612994c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 9,
      "beatId": "1f13dd9d-adda-48c7-ad5c-4e44ba8f57d7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases AstraZeneca's financial results, R&D highlights, and sustainability initiatives, providing a sense of satisfaction",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 5,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "8f711e18-1f16-4fa6-b2d7-b917fe429d2f",
      "evidence": "The presentation highlights multiple examples of AstraZeneca's growth and innovation across different disease areas",
      "position": 0,
      "objective": "To identify patterns and trends in AstraZeneca's growth and innovation",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}